Keyphrases
Fluvoxamine
100%
COVID-19
98%
Attention Deficit Hyperactivity Disorder
74%
Clinical Deterioration
57%
Long COVID
36%
Systematic Meta-analysis
36%
Meta-analysis
36%
Autistic Traits
32%
Treatment Efficacy
30%
DSM-IV
29%
Early Treatment
27%
Attention-deficit Hyperactivity Disorder Symptoms
26%
Selective Serotonin Reuptake Inhibitors
25%
Autistic Symptoms
25%
Autism Spectrum Disorder
21%
Social Responsiveness Scale
20%
Randomized Clinical Trial
19%
Hospitalization
19%
Placebo
19%
Older Adults
19%
Wolfram Syndrome
18%
Sigma-1 Receptor
16%
DRD4
16%
Clinical Trials
15%
Drug Repurposing
15%
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs)
14%
Antidepressant Use
14%
Substance Use
14%
Provisional Tic Disorder
14%
COVID-19 Pandemic
13%
Antidepressants
12%
Psychiatric Symptoms
12%
Disease Severity
11%
Randomized Controlled Trial
11%
Population-based
11%
Repurposing
10%
Alzheimer's Disease
10%
Genotype
10%
SARS-CoV-2 Infection
9%
Fluoxetine
9%
Clinically Significant
9%
Severe Coronavirus Disease 2019
9%
Psychosocial Challenges
9%
Inhibitory Control
9%
Sex Differences
8%
Patients with COVID-19
8%
Risk Reduction
8%
Child Behavior Checklist
8%
Genetic Influences
8%
Use Disorder
8%
Pharmacology, Toxicology and Pharmaceutical Science
Fluvoxamine
93%
Deterioration
57%
Diseases
44%
Coronavirinae
40%
Combination Therapy
29%
SARS Coronavirus
28%
Placebo
27%
Infection
21%
Selective Serotonin Reuptake Inhibitor
21%
Randomized Clinical Trial
21%
Clinical Trial
16%
Inflammation
14%
Alzheimer's Disease
14%
Malignant Neoplasm
14%
Antidepressant
12%
Randomized Controlled Trial
12%
Repurposing
11%
Attention Deficit Disorder
11%
Drug Repositioning
9%
Adverse Event
9%
Receptor
8%
Neuroprotection
7%
Cyproheptadine
7%
Bromhexine
7%
Psychotropic Agent
7%
Intubation
7%
Psychosis
7%
Side Effect
7%
Niclosamide
7%
Serotonin Reuptake Inhibitor
7%
Antipsychotic Drug
7%
Placebo-Controlled Study
7%
Sphingomyelin Phosphodiesterase
6%
Sigma 1 Opiate Receptor
6%